drug development
Q&A: From FDA to Industry
Q&A: From FDA to Industry
Kerry Grens | Sep 27, 2016
Among a subset of US Food and Drug Administration regulators who leave the agency, more than half go to work for pharmaceutical companies, researchers report.
Allergan’s Buying Spree Rolls On
Allergan’s Buying Spree Rolls On
Bob Grant | Sep 21, 2016
The Ireland-based pharma company makes a $1.7 billion offer to acquire Tobira Therapeutics, a US firm developing liver disease drugs.
Feds Demand More Clinical Trial Reporting
Feds Demand More Clinical Trial Reporting
Kerry Grens | Sep 19, 2016
Expanded US Health and Human Services rules will require the results of more human studies to be made public.
Allergan Set to Buy Vitae
Allergan Set to Buy Vitae
Bob Grant | Sep 16, 2016
The Irish drugmaker has made a $639 million dollar offer to buy the US-based biopharma.
The Challenges of Rare-Disease Research
The Challenges of Rare-Disease Research
Jyoti Madhusoodanan | Sep 1, 2016
With few resources and hesitant investors, basic scientists must rely on clinicians, patient advocates, and their own keen eye for biological connections.
Pfizer to Buy Medivation for $14 Billion
Pfizer to Buy Medivation for $14 Billion
Bob Grant | Aug 22, 2016
The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.
The Growth of Iowa Biotech
The Growth of Iowa Biotech
Jenny Rood | Aug 1, 2016
The state’s industry draws inspiration from medicine as well as agriculture.
Mystery Mechanisms
Mystery Mechanisms
Tanya Lewis | Jul 29, 2016
Scientists still don’t know exactly how some commonly used drugs work. Here’s a look at three such compounds.
FDA Reduces Paperwork for “Compassionate Use”
FDA Reduces Paperwork for “Compassionate Use”
Jef Akst | Jun 8, 2016
The change should allow patients with fatal illnesses easier access to experimental drugs, but gaining permission from drug companies remains the biggest challenge.
$1.5 Billion Pharma Buyout for Leukemia Drug
$1.5 Billion Pharma Buyout for Leukemia Drug
Jef Akst | Jun 1, 2016
Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.